Is there a role for use of GLP-1/GIP receptor agonists in the management of substance use disorders, whether or not they meet other inclusion criteria for their use?  

Currently, we lack the RCTs to understand the full impact of GLP-1s on SUD outcomes. Most evidence is pre-clinical, observational, suggesting potential reductions in cravings and alcohol use. A recent RCT, lab study of semaglutide in non-treatment-seeking adults with AUD showed decreased alcohol con...

There is no approval for the use of GLP1RA/GIPs in the management of substance use disorder yet, although this is an area of interest, and there is likely research ongoing. What we do know is that they act on some of that "reward center" circuit to the brain in that reward with eating a pleasurable ...